Abstract: The subject invention pertains to compositions and methods for inhibiting IGF2 signaling. Insulin-like growth factor 2 (IGF2) is a key signaling molecule that plays important roles in various physiological processes, including skeletal myogenesis during development and adult muscle remodeling. Abnormal activation of the signaling pathway induced by IGF2 has been shown to promote cancer progression. TMED10, a p24 family protein, functions as a cargo receptor, promoting the export of IGF2 from the endoplasmic reticulum (ER) via recognizing an ER export signal on IGF2. Moreover, TMED10 also mediates ER export of sortilin, which is important to regulate the export of IGF2 from the trans-Golgi network. The subject invention features a novel therapeutic strategy for cancer treatment, that includes, but is not limited to, inhibitors targeting the interaction between IGF2 and TMED10.

Abstract: The present invention relates to the discovery that delivery of EGFR to cell surface requires EGFR-SAR1A binding. Thus, the invention provides a method for identifying inhibitors of EGFR-SAR1A binding, which can serve as therapeutic agents for treating conditions involving undesirable EGFR signaling. The invention also provides novel composition and its use that suppresses the specific binding between EGFR and SAR1A for the purpose of treating or preventing a condition involving undesired EGFR signaling.

Abstract: The present invention relates to the discovery that delivery of EGFR to cell surface requires EGFR-SAR1A binding. Thus, the invention provides a method for identifying inhibitors of EGFR-SAR1A binding, which can serve as therapeutic agents for treating conditions involving undesirable EGFR signaling. The invention also provides novel composition and its use that suppresses the specific binding between EGFR and SAR1A for the purpose of treating or preventing a condition involving undesired EGFR signaling.